Cargando…
Cold Case of Thrombolysis: Cold Recombinant Tissue Plasminogen Activator Confers Enhanced Neuroprotection in Experimental Stroke
BACKGROUND: Thrombolysis and endovascular thrombectomy are the primary treatment for ischemic stroke. However, due to the limited time window and the occurrence of adverse effects, only a small number of patients can genuinely benefit from recanalization. Intraarterial injection of rtPA (recombinant...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547350/ https://www.ncbi.nlm.nih.gov/pubmed/37655472 http://dx.doi.org/10.1161/JAHA.123.029817 |
_version_ | 1785115043657940992 |
---|---|
author | Huang, Yuyou Gu, Shanshan Han, Ziping Yang, Zhenghong Zhong, Liyuan Li, Lingzi Wang, Rongliang Yan, Feng Luo, Yumin Borlongan, Cesario Lu, Jie |
author_facet | Huang, Yuyou Gu, Shanshan Han, Ziping Yang, Zhenghong Zhong, Liyuan Li, Lingzi Wang, Rongliang Yan, Feng Luo, Yumin Borlongan, Cesario Lu, Jie |
author_sort | Huang, Yuyou |
collection | PubMed |
description | BACKGROUND: Thrombolysis and endovascular thrombectomy are the primary treatment for ischemic stroke. However, due to the limited time window and the occurrence of adverse effects, only a small number of patients can genuinely benefit from recanalization. Intraarterial injection of rtPA (recombinant tissue plasminogen activator) based on arterial thrombectomy could improve the prognosis of patients with acute ischemic stroke, but it could not reduce the incidence of recanalization‐related adverse effects. Recently, selective brain hypothermia has been shown to offer neuroprotection against stroke. To enhance the recanalization rate of ischemic stroke and reduce the adverse effects such as tiny thrombosis, brain edema, and hemorrhage, we described for the first time a combined approach of hypothermia and thrombolysis via intraarterial hypothermic rtPA. METHODS AND RESULTS: We initially established the optimal regimen of hypothermic rtPA in adult rats subjected to middle cerebral artery occlusion. Subsequently, we explored the mechanism of action mediating hypothermic rtPA by probing reduction of brain tissue temperature, attenuation of blood–brain barrier damage, and sequestration of inflammation coupled with untargeted metabolomics. Hypothermic rtPA improved neurological scores and reduced infarct volume, while limiting hemorrhagic transformation in middle cerebral artery occlusion rats. These therapeutic outcomes of hypothermic rtPA were accompanied by reduced brain temperature, glucose metabolism, and blood–brain barrier damage. A unique metabolomic profile emerged in hypothermic rtPA‐treated middle cerebral artery occlusion rats characterized by downregulated markers for energy metabolism and inflammation. CONCLUSIONS: The innovative use of hypothermic rtPA enhances their combined, as opposed to stand‐alone, neuroprotective effects, while reducing hemorrhagic transformation in ischemic stroke. |
format | Online Article Text |
id | pubmed-10547350 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105473502023-10-04 Cold Case of Thrombolysis: Cold Recombinant Tissue Plasminogen Activator Confers Enhanced Neuroprotection in Experimental Stroke Huang, Yuyou Gu, Shanshan Han, Ziping Yang, Zhenghong Zhong, Liyuan Li, Lingzi Wang, Rongliang Yan, Feng Luo, Yumin Borlongan, Cesario Lu, Jie J Am Heart Assoc Original Research BACKGROUND: Thrombolysis and endovascular thrombectomy are the primary treatment for ischemic stroke. However, due to the limited time window and the occurrence of adverse effects, only a small number of patients can genuinely benefit from recanalization. Intraarterial injection of rtPA (recombinant tissue plasminogen activator) based on arterial thrombectomy could improve the prognosis of patients with acute ischemic stroke, but it could not reduce the incidence of recanalization‐related adverse effects. Recently, selective brain hypothermia has been shown to offer neuroprotection against stroke. To enhance the recanalization rate of ischemic stroke and reduce the adverse effects such as tiny thrombosis, brain edema, and hemorrhage, we described for the first time a combined approach of hypothermia and thrombolysis via intraarterial hypothermic rtPA. METHODS AND RESULTS: We initially established the optimal regimen of hypothermic rtPA in adult rats subjected to middle cerebral artery occlusion. Subsequently, we explored the mechanism of action mediating hypothermic rtPA by probing reduction of brain tissue temperature, attenuation of blood–brain barrier damage, and sequestration of inflammation coupled with untargeted metabolomics. Hypothermic rtPA improved neurological scores and reduced infarct volume, while limiting hemorrhagic transformation in middle cerebral artery occlusion rats. These therapeutic outcomes of hypothermic rtPA were accompanied by reduced brain temperature, glucose metabolism, and blood–brain barrier damage. A unique metabolomic profile emerged in hypothermic rtPA‐treated middle cerebral artery occlusion rats characterized by downregulated markers for energy metabolism and inflammation. CONCLUSIONS: The innovative use of hypothermic rtPA enhances their combined, as opposed to stand‐alone, neuroprotective effects, while reducing hemorrhagic transformation in ischemic stroke. John Wiley and Sons Inc. 2023-09-01 /pmc/articles/PMC10547350/ /pubmed/37655472 http://dx.doi.org/10.1161/JAHA.123.029817 Text en © 2023 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Research Huang, Yuyou Gu, Shanshan Han, Ziping Yang, Zhenghong Zhong, Liyuan Li, Lingzi Wang, Rongliang Yan, Feng Luo, Yumin Borlongan, Cesario Lu, Jie Cold Case of Thrombolysis: Cold Recombinant Tissue Plasminogen Activator Confers Enhanced Neuroprotection in Experimental Stroke |
title | Cold Case of Thrombolysis: Cold Recombinant Tissue Plasminogen Activator Confers Enhanced Neuroprotection in Experimental Stroke |
title_full | Cold Case of Thrombolysis: Cold Recombinant Tissue Plasminogen Activator Confers Enhanced Neuroprotection in Experimental Stroke |
title_fullStr | Cold Case of Thrombolysis: Cold Recombinant Tissue Plasminogen Activator Confers Enhanced Neuroprotection in Experimental Stroke |
title_full_unstemmed | Cold Case of Thrombolysis: Cold Recombinant Tissue Plasminogen Activator Confers Enhanced Neuroprotection in Experimental Stroke |
title_short | Cold Case of Thrombolysis: Cold Recombinant Tissue Plasminogen Activator Confers Enhanced Neuroprotection in Experimental Stroke |
title_sort | cold case of thrombolysis: cold recombinant tissue plasminogen activator confers enhanced neuroprotection in experimental stroke |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547350/ https://www.ncbi.nlm.nih.gov/pubmed/37655472 http://dx.doi.org/10.1161/JAHA.123.029817 |
work_keys_str_mv | AT huangyuyou coldcaseofthrombolysiscoldrecombinanttissueplasminogenactivatorconfersenhancedneuroprotectioninexperimentalstroke AT gushanshan coldcaseofthrombolysiscoldrecombinanttissueplasminogenactivatorconfersenhancedneuroprotectioninexperimentalstroke AT hanziping coldcaseofthrombolysiscoldrecombinanttissueplasminogenactivatorconfersenhancedneuroprotectioninexperimentalstroke AT yangzhenghong coldcaseofthrombolysiscoldrecombinanttissueplasminogenactivatorconfersenhancedneuroprotectioninexperimentalstroke AT zhongliyuan coldcaseofthrombolysiscoldrecombinanttissueplasminogenactivatorconfersenhancedneuroprotectioninexperimentalstroke AT lilingzi coldcaseofthrombolysiscoldrecombinanttissueplasminogenactivatorconfersenhancedneuroprotectioninexperimentalstroke AT wangrongliang coldcaseofthrombolysiscoldrecombinanttissueplasminogenactivatorconfersenhancedneuroprotectioninexperimentalstroke AT yanfeng coldcaseofthrombolysiscoldrecombinanttissueplasminogenactivatorconfersenhancedneuroprotectioninexperimentalstroke AT luoyumin coldcaseofthrombolysiscoldrecombinanttissueplasminogenactivatorconfersenhancedneuroprotectioninexperimentalstroke AT borlongancesario coldcaseofthrombolysiscoldrecombinanttissueplasminogenactivatorconfersenhancedneuroprotectioninexperimentalstroke AT lujie coldcaseofthrombolysiscoldrecombinanttissueplasminogenactivatorconfersenhancedneuroprotectioninexperimentalstroke |